Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Profit After Tax (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Profit After Tax for 6 consecutive years, with -$6.6 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 58.39% to -$6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.4 million through Dec 2025, up 47.12% year-over-year, with the annual reading at -$33.4 million for FY2025, 47.12% up from the prior year.
  • Profit After Tax hit -$6.6 million in Q4 2025 for Bolt Biotherapeutics, up from -$7.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$6.6 million in Q4 2025 to a low of -$27.2 million in Q4 2021.
  • Historically, Profit After Tax has averaged -$17.6 million across 5 years, with a median of -$18.0 million in 2023.
  • Biggest five-year swings in Profit After Tax: tumbled 183.26% in 2021 and later surged 59.61% in 2025.
  • Year by year, Profit After Tax stood at -$27.2 million in 2021, then increased by 26.37% to -$20.0 million in 2022, then grew by 10.47% to -$17.9 million in 2023, then grew by 10.99% to -$15.9 million in 2024, then skyrocketed by 58.39% to -$6.6 million in 2025.
  • Business Quant data shows Profit After Tax for BOLT at -$6.6 million in Q4 2025, -$7.1 million in Q3 2025, and -$8.6 million in Q2 2025.